Syndax Pharmaceuticals SNDX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's accrued expenses and other liabilities?
- Syndax Pharmaceuticals (SNDX) reported accrued expenses and other liabilities of $74.84M in Q1 2026.
- How has Syndax Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Syndax Pharmaceuticals's accrued expenses and other liabilities increased by 33.7% year-over-year, from $55.98M to $74.84M.
- What is the long-term trend for Syndax Pharmaceuticals's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's accrued expenses and other liabilities has grown at a 33.5% compound annual growth rate (CAGR), from $24.28M to $103.06M.